Esperion Therapeutics (ESPR) Inventory Average (2020 - 2026)

Esperion Therapeutics' Inventory Average history runs 7 years deep, the most recent figure standing at $104.7 million for Q1 2026.

• Quarterly Inventory Average rose 8.01% year-over-year to $104.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.7 million (up 8.01% YoY) and the FY2025 annual result came in at $99.8 million, up 24.67% from the prior year.
• Inventory Average was $104.7 million for Q1 2026 at Esperion Therapeutics, down from $106.8 million in the prior quarter.
• Across five years, Inventory Average topped out at $111.5 million in Q3 2025 and bottomed at $29.4 million in Q3 2022.
• A 5-year average of $68.3 million and a median of $69.4 million in 2024 frame the typical range for Inventory Average.
• Peak annual rise in Inventory Average reached 93.68% in 2022, while the deepest fall reached 5.3% in 2022.
• Esperion Therapeutics' Inventory Average stood at $32.4 million in 2022, then soared by 80.8% to $58.5 million in 2023, then jumped by 49.15% to $87.3 million in 2024, then grew by 22.38% to $106.8 million in 2025, then fell by 2.03% to $104.7 million in 2026.
• Business Quant data shows ESPR's Inventory Average at $104.7 million in Q1 2026, $106.8 million in Q4 2025, and $111.5 million in Q3 2025.